Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma?

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
N SamniahD G Benditt

Abstract

A 30-year-old Caucasian male was referred for evaluation of a 2-year history of recurrent post-exertion lightheadedness and near syncopal spells in the setting of a family history of unexplained sudden cardiac death. Cardiac evaluation demonstrated normal heart structure, but the 12-lead surface ECG was suggestive of but not diagnostic of Brugada syndrome. An exercise stress test reproduced the patient's usual symptoms during the recovery period, and was consistent with a typical vasovagal faint. The same symptoms were observed during a head-up tilt table test. However, given the family history and ECG, pharmacological testing with procainamide, isoprenaline and metoprolol, as well as programmed ventricular stimulation, were undertaken. Pharmacological provocation further supported a diagnosis of Brugada syndrome, whereas programmed ventricular stimulation was considered non-diagnostic regarding ventricular tachyarrhythmia susceptibility. Consequently, despite ECG and pharmacological findings suggestive of Brugada syndrome, there appeared to be sufficient evidence to believe that this patient's symptoms were the result of neurally mediated syncope and not due to ventricular tachyarrhythmias. The patient was treated with midodri...Continue Reading

Citations

Aug 25, 2007·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·Teresa DonnellyDeclan Lyons
Aug 9, 2002·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Takanori Ikeda
Jun 1, 2012·Cardiac Electrophysiology Clinics·Troy Rhodes, Raul Weiss
Aug 18, 2005·Pacing and Clinical Electrophysiology : PACE·Manlio F MárquezManuel Cárdenas
Apr 1, 2008·Pacing and Clinical Electrophysiology : PACE·Konstantinos P LetsasFotios Kardaras
Feb 24, 2006·Pacing and Clinical Electrophysiology : PACE·Nicolino Patruno, Daniele Pontillo
Oct 2, 2009·Journal of Cardiovascular Electrophysiology·Miki YokokawaWataru Shimizu
May 11, 2005·International Journal of Cardiology·Johnson Francis, Charles Antzelevitch
Apr 3, 2007·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Naomasa MakitaHiroyuki Tsutsui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Pedro BrugadaRamon Brugada
Pacing and Clinical Electrophysiology : PACE
Manlio F MárquezManuel Cárdenas
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Pedro Brugada
© 2021 Meta ULC. All rights reserved